Skip to main navigation
Skip to search
Skip to main content
Sort by
INIS
patients
100%
therapy
44%
diseases
34%
anticoagulants
33%
risks
33%
coronaries
21%
interventions
21%
heparin
17%
thrombosis
14%
laboratories
14%
management
14%
coronaviruses
13%
comparative evaluations
12%
inflammation
12%
kidneys
12%
prothrombin
11%
monitoring
11%
ischemia
10%
thrombin
10%
conferences
10%
atherosclerosis
9%
data
9%
molecular weight
8%
fibrinolysis
8%
recommendations
8%
emergencies
8%
vitamin k
8%
fibrinogen
8%
plasminogen
7%
testing
7%
Keyphrases
Maastricht
26%
Direct Oral Anticoagulants
21%
Rotational Thromboelastometry (ROTEM)
20%
Percutaneous Coronary Intervention
19%
Intensive Care
16%
Coronavirus Disease (COVID)
16%
Clinical High Risk
15%
Atherothrombosis
15%
Antithrombotic Therapy
14%
Thrombosis
13%
Bleeding
12%
Dual Antiplatelet Therapy
12%
Low Molecular Weight Heparin
11%
Platelet Function Tests
11%
Hemostasis
11%
Prothrombin Complex Concentrate
10%
Triple Antithrombotic Therapy
10%
Consensus Conference
10%
Unfractionated Heparin
10%
Peripheral Arterial Disease
10%
Oral Anticoagulants
10%
COVID-19
9%
Multiplate
9%
Fibrinogen
9%
Dual Antithrombotic Therapy
9%
Bleeding Risk
9%
P2Y12 Inhibitors
8%
Venous Thromboembolism
8%
Anticoagulants
8%
Vitamin K Antagonists
8%
Medicine and Dentistry
COVID-19
25%
Antithrombotic Therapy
21%
Direct Oral Anticoagulant
21%
Thromboelastometry
19%
Thrombosis
17%
Antithrombotic
16%
Intensive Care
15%
Percutaneous Coronary Intervention
15%
Heparin
11%
Bleeding
11%
Blood Stasis
10%
Blood Clotting
10%
Thromboembolism
10%
Prothrombin Complex
10%
Anticoagulation
8%
Acetylsalicylic Acid
8%
Vitamin K Antagonist
8%
Atherosclerosis
7%
Fibrinolysis
7%
Arteriosclerosis Obliterans
7%
Fibrinogen
7%
Venous Thromboembolism
7%
Laboratory Test
6%
Anticoagulant
6%
Platelet
6%
Cardiovascular Disease
6%
Blood Clotting Factor 10a Inhibitor
6%
Observational Study
5%
Thrombocyte Function
5%
Function Test
5%
